Treatment of Upper Respiratory Infectio

Phase 3

Recruiting

• Conditions: Condition 1: Acute nasopharyngitis. Condition 2: Acute sinusitis. Condition 3: Acute pharyngitis. Condition 4: Acute tonsillitis. Condition 5: Acute laryngitis and tracheitis. Condition 6: Acute obstructive laryngitis [croup] and epiglottitis. Condition 7: Acute upper respiratory infections of multiple and unspecified sites.; Acute nasopharyngitis [common cold]; Acute sinusitis; Acute pharyngitis; Acute tonsillitis; Acute obstructive laryngitis [croup] and epiglottitis; Acute upper respiratory infections of multiple and unspecified sites; Acute laryngitis and tracheitis

• Registration Number: IRCT20210913052453N2
• Lead Sponsor: Asadabad University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 27 June 2022

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 1000

Inclusion Criteria

Body Temperature > 37.5ºC and highest point <39ºC within 24hours of enrollment,
Within 12 hours of screening, three or more of the following main symptoms: Nasal Congestion, Rhinorrhea, Sore and/or scratchy throat, sneezing, headache, muscle or body aches, or malaise.
The subject has signed the informed consent form.

Exclusion Criteria

Other Respiratory diseases or acute and chronic nasal diseases or abnormal nasal mucosal function after nasal surgery or nasopharyngeal radiotherapy
Severe primary health conditions associated with cardiovascular, cerebrovascular, pulmonary, hepatic, renal, endocrine and hematological diseases, hematopoietic system and mental illness or serious diseases affecting their survival, such as cancer or AIDS
With severe cardiopulmonary dysfunction, cardiopulmonary insufficiency
Subjects, who were treated with other Chinese and western drugs (including drugs for common cold, antiviral, antibiotics, and similar traditional Chinese medicine) and antipyretic and analgesic drugs within 6 hours before enrollment.
Allergic individuals and those who are known to be allergic to experimental drugs.
Pregnant women, and lactating women
Subject, who has participated in the past 1 month in another clinical study.
Subjects who are not suitable for the clinical trial based on investigators’ judgment.
Subjects who consume alcohol.

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Curative Rate Evaluation. Timepoint: Measure the body temperature by treatment day 2/3/4/5. Method of measurement: In this study, data are obtained based on clinical and laboratory studies.;Lab tests (Improvement in Lymphocyte count, CRP, ESR levels etc.). Timepoint: Measurements will be taken before and after the treatment period. Method of measurement: In this study, data are obtained based on clinical and laboratory studies.